CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 200 enrolled
Drug / intervention
Not specified
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT06960538
NCT06960538N/ACompleted

PRIORITY (Enpowering Progression Risk of Cerebral Amyloid Angiopathy)

Fondazione I.R.C.C.S. Istituto Neurologico Carlo Besta·observational·Posted May 7, 2025·Updated Mar 27, 2026

In Brief

An observational study for Cerebral Amyloid Angiopathy and CAA - Cerebral Amyloid Angiopathy. Completed, enrolled 200 participants across 1 site.

Detailed Summary

Cerebral amyloid angiopathy (CAA) is a microangiopathy characterized by the progressive deposition of β-amyloid in cerebral vessel walls, contributing to intracerebral hemorrhages, cognitive decline, and other clinical manifestations. Despite recent advances in diagnosis and understanding, many pathogenic, prognostic, and therapeutic aspects remain unclear. Study Objective: PRIORITY is a prospective observational study aimed at identifying clinical, neuroradiological, and biochemical biomarkers that could improve early diagnosis, risk stratification, and the identification of personalized therapeutic targets for CAA.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
CountriesItaly
Collaborators--

Timeline

N/ACompletedFinished
20222023202420252026
First PostedMay 7, 2025
Enrollment StartNov 1, 2021
Primary CompletionSep 30, 2025
TodayJul 2, 2026
Enrollment to primary: 3.9 yearsPosted 1.2 years ago